PYC (ASX) PYC Filed Another Patent

Originally posted by Medicine Man: ↑

PYC has filed another patent "Advanced compositions and methods for treatment of kidney disease 2" on 06/05/2024.

As commented in my last post 73242059, this is another "Advanced" compositions and methods patent.

If it is related to ADPKD, it might be a better way of treating the disease, For example, delivering the drug with greater affinity to accumulate in the kidney tissues and/or having higher efficacy. Whichever way, this would add value to the the drug. With higher precision in targeting the drug to the kidney, a lower dosage would produce the same or even higher efficacy, hand-in-hand lower with toxicity. These would certainly de-risk and improve the chance of FDA approval.

If it is NOT related to the ADPKD drug already in the pipeline, it would be more interesting as adding the 5th drug to the pipeline would increase PYC's valuation!. Another US$1b, 5b, or more...?

There are many genetic kidney diseases with early onset affecting baby at birth. Common ones are summarised below for you to get up to speed quickly:

Autosomal recessive polycystic kidney disease (ARPKD) is caused by a mutation in chromosome 6 (PKHD1 gene). It can cause death in the first month of life, almost 80% of ARPKD children survive the newborn period. Past that, one-third will need a transplant or dialysis in the first 10 years. ARPKD affects both kidneys and the liver and can impact lung development, blood pressure, and gastrointestinal health.

Genetic Nephrotic syndrome is a kidney disorder that causes your body to pass too much protein in urine. Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in your kidneys that filter waste and excess water from your blood. The condition causes swelling, particularly in the feet and ankles, and increases the risk of other health problems such as elevated risk of infections and blood clots.

Focal segmental glomerulosclerosis (FSGS) is a disease in which scar tissue develops on the glomeruli, the small parts of the kidneys that filter waste from the blood. Symptoms might include swelling, called edema in the legs and ankles, around the eyes and in other body parts, weight gain from fluid buildup, and foamy urine from protein buildup, called proteinuria.

Alport Syndrome causes one’s kidney function to decline over time and can also result in hearing loss and eye abnormalities. A small percentage of X-linked Alport syndrome patients experience leiomyomas, benign (not cancerous) smooth muscle tumors that can be found in the esophagus, lungs, uterus, and other female reproductive organs. Prevalence is estimated to be less than 200,000 people in the U.S.

The above list is not exhaustive and only serves to illustrate the severity of these genetic kidney diseases which could be life threatening even in the first month of life. As these are rare diseases, many big pharmas might rather focus on more lucrative ventures, developing a precision medicine to help these sufferers would certainly bring many levels of enlightenment to the team at PYC. Good on you!

I have already asked Rohan to comment on these "Advanced" patents in the Investors' Meeting on 09/05/2024. I sincerely hope he is in the position to shed more lights on this subject. Every patent costs a lot of manpower and money to prepare and to file. They are strategic in order to protect PYC's intellectual properties. Therefore with each filing, it gives me MORE CONFIDENCE of success and let more sufferers to have relief. For the investors, it would translate to higher company valuation and higher share price! DYOR

If you find it useful, please click the Good Analysis button below

Expand

I wonder whether this latest patent application could have anything to do with PYC pursuing AI-driven drug discovering as a result of their collaboration with Google Cloud. It would be an amazing step, to come to the fore so soon, possibly PYC had this on their radar and the Ai driven computational algorithms were able to confirm or assist with defining suitability?

Another question for Rohan?

No.	Vol.	Price($)
1	5000	$1.18

No.

Vol.

Price($)

5000

$1.18

Price($)	Vol.	No.
$1.20	19651	3

Price($)

Vol.

No.

$1.20

19651

No.	Vol.	Price($)
1	5000	1.175
4	77891	1.150
1	50000	1.140
1	6756	1.130
1	889	1.125

No.

Vol.

Price($)

5000

1.175

77891

1.150

50000

1.140

6756

1.130

889

1.125

Price($)	Vol.	No.
1.200	19651	3
1.205	2270	1
1.210	6000	1
1.220	5596	2
1.230	15000	1

Price($)

Vol.

No.

1.200

19651

1.205

2270

1.210

6000

1.220

5596

1.230

15000

(20min delay)
Last $1.20		Change 0.040(3.45%)		Mkt cap ! $699.9M

Open	High	Low	Value	Volume
$1.19	$1.20	$1.18	$97.44K	81.86K

I wonder whether this latest patent application could have...

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Recce locks in $30M to boost commercialisation across ASEAN region

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I wonder whether this latest patent application could have...

Top Stories

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Recce locks in $30M to boost commercialisation across ASEAN region

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News